Positives

• Hospitalized patients given IV remdesivir during acute COVID commonly report less post-COVID fatigue, dyspnea, and concentration loss as they recover PMC.
• Hospitalized acute COVID patients on a 5- or 10-day remdesivir course commonly recover faster New England Journal of Medicine.

Negatives

• Patients given remdesivir for acute COVID commonly see no improvement in their long-term symptoms or recovery, per the Solidarity Finland follow-up Communications Medicine.
• A 2023 systematic review concluded the evidence on antivirals preventing Long COVID is conflicting, with several trials showing no Long COVID benefit from remdesivir PubMed.

Hurdles & Side Effects

• Remdesivir is administered IV daily for 3-5 days in a hospital or infusion-clinic setting; outpatient access expanded after 2022 but availability for Long COVID prevention remains limited to acute infection within the first 7 days of symptoms University of Illinois Chicago.
  
  
• Acute side effects can include transaminase elevation, infusion reactions, and rare bradycardia; the cost (about $520 per vial in the US, with multiple vials per course) puts it out of reach for outpatients without insurance authorization NIH.